Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Phase 2/3 Completed
101 enrolled 15 charts
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase 1/2 Completed
107 enrolled 24 charts
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
125 enrolled 12 charts
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
Phase 1 Completed
33 enrolled
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase 1/2 Completed
79 enrolled 17 charts
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Phase 2 Completed
30 enrolled 16 charts
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase 2 Completed
60 enrolled
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Phase 1/2 Completed
52 enrolled 12 charts
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Phase 2 Completed
32 enrolled 11 charts
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Phase 3 Completed
754 enrolled 20 charts
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Phase 1 Completed
7 enrolled
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
Phase 1/2 Completed
96 enrolled 15 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Phase 2 Completed
37 enrolled 8 charts
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2 Completed
16 enrolled 9 charts
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
Phase NA Completed
12 enrolled 8 charts
Vorinostat in Treating Patients With Kidney Cancer
Phase 2 Completed
14 enrolled 7 charts
TARGET
Phase 2 Completed
19 enrolled 12 charts
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
17 enrolled
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1/2 Completed
37 enrolled 6 charts
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase 1 Completed
29 enrolled
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
Phase 1/2 Completed
54 enrolled 9 charts
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
94 enrolled 8 charts
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
80 enrolled
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
Phase 2 Completed
19 enrolled 11 charts
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Completed
60 enrolled
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
Phase 2 Completed
29 enrolled 8 charts
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
Phase 2 Completed
27 enrolled 9 charts
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Phase 2 Completed
103 enrolled 10 charts
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
37 enrolled 11 charts
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
Phase 2 Completed
44 enrolled 9 charts
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
Phase 2 Completed
16 enrolled 6 charts
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
66 enrolled
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
21 enrolled
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
Phase 1 Completed
54 enrolled
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
Phase 1 Completed
40 enrolled
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
Phase 1 Completed
40 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 1 Completed
25 enrolled
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Phase 1 Completed
24 enrolled
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
40 enrolled
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
Phase 1 Completed
50 enrolled